^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PIK3CB expression

i
Other names: PIK3CB, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta, Phosphatidylinositol 4,5-Bisphosphate 3-Kinase 110 KDa Catalytic Subunit Beta, Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Isoform, Phosphoinositide-3-Kinase, Catalytic, Beta Polypeptide, PtdIns-3-Kinase Subunit P110-Beta, PtdIns-3-Kinase Subunit Beta, PI3-Kinase Subunit Beta, PI3K-Beta, PIK3C1, PI3-Kinase P110 Subunit Beta, PtdIns-3-Kinase P110, P110BETA, PI3KBETA, PI3Kbeta, P110beta
Entrez ID:
Related biomarkers:
over1year
Circular RNA Fibroblast Growth Factor Receptor 1 Promotes Pancreatic Cancer Progression by Targeting MicroRNA-532-3p/PIK3CB Axis. (PubMed, Pancreas)
Our data revealed that circFGFR1 driven the malignant progression of PDAC by targeting miR-532-3p/PIK3CB axis, suggesting that inhibition of circFGFR1 might be considered as a therapeutic target for PDAC.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • MIR532 (MicroRNA 532)
|
FGFR1 expression • PIK3CB expression
almost2years
Evaluating the role of the PIK3CB pathway in temozolomide resistance in glioblastoma using the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) databases (SNO 2022)
We found that AKT phosphorylation and PIK3CB mRNA data together performed better as a biomarker in predicting therapeutic response to p110β-selective inhibitors than each variable alone, specifically we found that AKT phosphorylation at T308 was negatively related to p110β-selective inhibitor AZD6482 sensitivity at low PIK3CB expression levels (B = -0.069, p = 0.0513) and this relationship disappeared at higher expression levels (B = 0.04, p = 0.176) with an interaction at near statistical significance (p = 0.0674). While AKT phosphorylation is currently used as a biomarker for PI3K pathway inhibitors, in this study, we demonstrate that both PIK3CB mRNA and AKT phosphorylation together was a significant biomarker in sensitivity to p110β inhibitors as compared to assessing each independently. Furthermore, PIK3CB was implicated in TMZ resistance in GBM as compared to other catalytic isoforms.
Preclinical
|
PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
|
PIK3CB expression
|
temozolomide • AZD6482
almost2years
PIK3CB promotes oesophageal cancer proliferation through the PI3K/AKT/mTOR signalling axis. (PubMed, Cell Biol Int)
In conclusion, PIK3CB promotes ESCC by activating the PI3K/AKT/mTOR signalling axis. PIK3CB may be a potential target in ESCC.
Journal
|
PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
|
PIK3CB expression
2years
The expression and prognostic significance of PIK3CB in lung adenocarcinoma. (PubMed, Ann Diagn Pathol)
High PIK3CB expression was associated with the development of LUAD and worse prognosis. PIK3CB was an independent risk factor for LUAD patients. Therefore, this study provides a reliable reference for the prognostic assessment and targeted therapy for LUAD patients.
Journal
|
PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)
|
PIK3CB expression
2years
Mining database and verification of PIK3CB as a marker predicting prognosis and immune infiltration in renal clear cell carcinoma. (PubMed, Medicine (Baltimore))
Our study suggested that PIK3CB was a potential biomarker for prognosis and correlated with immune infiltrates in KIRC.
Journal
|
PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
|
PIK3CB expression
almost3years
PIK3CB is involved in metastasis through the regulation of cell adhesion to collagen I in pancreatic cancer. (PubMed, J Adv Res)
Collectively, our findings indicate that PIK3CB is involved in PAAD metastasis through cell-matrix adhesion. We proposed that PIK3CB is a potential therapeutic target for PAAD therapy.
Journal
|
PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
|
PIK3CB expression